Twice against thrice-weekly hemodialysis (TATH): a multicenter nonrandomized trial.

ABSTRACT:

Background

The optimal frequency of maintenance hemodialysis remains a subject of debate. In many countries, twice-weekly hemodialysis is still commonly practiced. This trial aimed to compare the outcomes of patients undergoing twice-weekly versus thrice-weekly hemodialysis.

Methods

This prospective, multicenter, nonrandomized trial included incident adult patients, with chronic kidney disease stage 5, initiating hemodialysis between January 2018 and August 2021. Patients were allocated to either a twice-weekly or thrice-weekly regimen, and monitored at 1, 3, 6, 12 and 24 months. This trial was terminated before reaching the required sample size due to the COVID-19 pandemic and economic factors. Recruitment achieved 25% of the projected number. Missing baseline factors were

SUBMITTER: Aoun M 

PROVIDER: S-EPMC11972488 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature